JP6329487B2 - ２型糖尿病の治療プロトコル - Google Patents

２型糖尿病の治療プロトコル Download PDF

Info

Publication number
JP6329487B2
JP6329487B2 JP2014537630A JP2014537630A JP6329487B2 JP 6329487 B2 JP6329487 B2 JP 6329487B2 JP 2014537630 A JP2014537630 A JP 2014537630A JP 2014537630 A JP2014537630 A JP 2014537630A JP 6329487 B2 JP6329487 B2 JP 6329487B2
Authority
JP
Japan
Prior art keywords
pharmaceutical combination
treatment
patients
combination according
lixisenatide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501314A (ja
Inventor
ルイーズ・シルヴェストル
エリザベト・スアミ
シャオダン・ウエイ
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2015501314A publication Critical patent/JP2015501314A/ja
Application granted granted Critical
Publication of JP6329487B2 publication Critical patent/JP6329487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2014537630A 2011-10-28 2012-10-26 ２型糖尿病の治療プロトコル Active JP6329487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187169.5 2011-10-28
EP11187169 2011-10-28
PCT/EP2012/071271 WO2013060850A1 (en) 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2

Publications (2)

Publication Number Publication Date
JP2015501314A JP2015501314A (ja) 2015-01-15
JP6329487B2 true JP6329487B2 (ja) 2018-05-23

Family

ID=47071308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537630A Active JP6329487B2 (ja) 2011-10-28 2012-10-26 ２型糖尿病の治療プロトコル

Country Status (15)

Country Link
US (1) US20130296236A1 (enExample)
EP (1) EP2771024B1 (enExample)
JP (1) JP6329487B2 (enExample)
KR (1) KR101967941B1 (enExample)
CN (2) CN104066441A (enExample)
AU (1) AU2012328388B2 (enExample)
BR (1) BR112014010200A2 (enExample)
CA (1) CA2851690C (enExample)
IL (1) IL232251B (enExample)
IN (1) IN2014CN02616A (enExample)
MX (1) MX359329B (enExample)
MY (1) MY170713A (enExample)
RU (1) RU2014121386A (enExample)
SG (1) SG11201401175SA (enExample)
WO (1) WO2013060850A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014209630A2 (en) * 2013-06-27 2014-12-31 Inspark Technologies, Inc. Systems, devices, and/or methods for identifying time periods of insufficient blood glucose testing
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
EP3091965A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AU2015359376B2 (en) * 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI706779B (zh) * 2015-01-16 2020-10-11 德商賽諾菲阿凡提斯德意志有限公司 小兒第２型糖尿病病患之治療
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) * 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20060287251A1 (en) * 2003-09-02 2006-12-21 Hans-Ulrich Demuth Combination therapy for glycaemic control
CA2573856A1 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US20120053843A1 (en) * 2009-02-04 2012-03-01 Sanofi-Aventis Deutschland Gmbh Medical device and method for providing information for glycemic control
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
ME01546B (me) * 2009-11-13 2014-04-20 Sanofi Aventis Deutschland Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
KR20110052990A (ko) * 2009-11-13 2011-05-19 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin

Also Published As

Publication number Publication date
JP2015501314A (ja) 2015-01-15
MX2014005139A (es) 2014-08-27
CN107693783A (zh) 2018-02-16
CN104066441A (zh) 2014-09-24
IL232251B (en) 2019-10-31
SG11201401175SA (en) 2014-09-26
RU2014121386A (ru) 2015-12-10
AU2012328388A1 (en) 2014-05-15
KR101967941B1 (ko) 2019-04-10
MX359329B (es) 2018-09-25
EP2771024A1 (en) 2014-09-03
WO2013060850A1 (en) 2013-05-02
CA2851690C (en) 2022-07-26
KR20140093935A (ko) 2014-07-29
BR112014010200A2 (pt) 2020-10-27
AU2012328388B2 (en) 2017-06-15
CA2851690A1 (en) 2013-05-02
IN2014CN02616A (enExample) 2015-06-26
US20130296236A1 (en) 2013-11-07
IL232251A0 (en) 2014-06-30
HK1198577A1 (en) 2015-04-30
EP2771024B1 (en) 2018-11-28
MY170713A (en) 2019-08-27

Similar Documents

Publication Publication Date Title
JP2015501314A (ja) ２型糖尿病の治療プロトコル
JP6410604B2 (ja) ２型糖尿病における基礎インスリンに対する上乗せ療法としてのリキシセナチド
JP6199186B2 (ja) ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
DK2750699T3 (en) A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
DK3010530T3 (en) FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
KR20140043756A (ko) 2형 당뇨병 환자에서 체중 감소를 유도하고/하거나 2형 당뇨병 환자에서 체중 증가를 예방하는데 사용하기 위한 약제학적 병용물
JP6857129B2 (ja) ２型糖尿病患者処置
HK1198577B (en) Treatment protocol of diabetes type 2
TW201322994A (zh) 第二型糖尿病的治療方案

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170421

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170428

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180420

R150 Certificate of patent or registration of utility model

Ref document number: 6329487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250